You are here

National TB Guidelines, Policies and Plans

South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017

Oct 2019
 South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017

The 2017 HIV and Health Study is the fifth wave of a series of cross-sectional surveys undertaken by a research consortium led by the Human Sciences Research Council (HSRC) every few years.

South African National LGBTI HIV Plan: 2017-2022

Oct 2018

The South African National LGBTI HIV Plan, 2017-2022 (LGBTI HIV Plan) is a milestone in the country’s response to HIV, AIDS, STIs, and TB. A national, multi-sectoral effort to address the linked HIV, TB and STI epidemics among Lesbian, Gay, Bisexual, Trans* and Intersex (LGBTI) people is urgent and somewhat overdue. Due to HIV vulnerabilities that are unique to each sub-group, there is a need for a strategic document that focuses on the LGBTI groups to support the National Strategic Plan on HIV, STIs and TB 2017-2022.

Interim Clinical Guidance for the Implementation of Injectable-Free Regimens for Rifampicin-Resistant Tuberculosis in Adults, Adolescents and Children

Oct 2018

This document provides interim clinical guidance on implementation of the modified short and long treatment regimens for people with Rifampicin Resistant Tuberculosis (RR-TB) in South Africa. National guidelines will be revised in 2019 following publication of the updated WHO policy guidelines on MDR-TB treatment (expected later in 2018).

NDOH Annual Performance Plan 2018/2019-2020/2021

Dec 2017

FOREWORD BY THE MINISTER OF HEALTH

If nobility is defined as having qualities or showing acts such as social justice, social solidarity, caring, honesty, generosity and courage to strive for what is good, then National Health Insurance (NHI) is not only a noble concept but a wise public investment for public good.

Summary Report on Decentralised and Deinstitutionalised Management of Multi-Drug Resistant Tuberculosis Services in South Africa

Oct 2017

Drug resistance is a major challenge in the control of Tuberculosis (TB), which itself remains a global public health concern. The incidence of Multi-drug Resistant (MDR) and Extensively Drug-resistant (XDR) TB is increasing, with an incidence rate of 70 per 100,000 people amidst a TB-HIV co-infection proportion estimated to be 60 to 80% in South Africa. In 2016 the World Health Organization (WHO) reported that South Africa has the 6th highest incidence of TB cases and the 5th highest number of Drug-Resistant TB cases in the world.

South Africa's National Strategic Plan on HIV, TB and STI's 2017-2022

Mar 2017
South Africa's National Strategic Plan on HIV, TB and STI's 2017-2022

The South African National Strategic Plan on HIV, TB and STIs 2017 - 2022 (NSP) serves as a roadmap for the next stage of our journey towards a future where these three diseases are no longer public health problems. This plan sets out the destinations – or goals – of our shared journey and establishes landmarks in the form of specific measurable objectives.

The purpose of the NSP is to enable the many thousands of organisations and individuals who drive the response to HIV, TB and STIs to act as a concerted force, moving in the same direction.

National Infection Prevention Control Guideline for TB, MDR-TB and XDR-TB

Dec 2015

Most people with undiagnosed, untreated and potentially contagious TB are frequently seen in health care facilities but are missed. In an area with high HIV prevalence, this poses a risk for HIV positive patients who are particularly vulnerable to TB with a 10% annual risk of developing TB compared to a 10% lifetime risk in those with normal immunity.

NDOH Management of Drug-resistant Tuberculosis Policy Guidelines

Jan 2013

EXECUTIVE SUMMARY

Key Issues in the Management of Drug-Resistant Tuberculosis

  1. Multidrug-resistant tuberculosis (MDR-TB) is defined as tuberculosis (TB) disease where there is in vitro resistance to both isoniazid and rifampicin, with or without resistance to other anti-TB drugs. As isoniazid and rifampicin are the two most important first-line TB drugs, their removal through resistance from the anti-TB drug armamentarium has serious implications.
Subscribe to National TB Guidelines, Policies and Plans